WAY 316606
Based on 4 publication(s) in Google Scholar
WAY 316606 is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC50 of 0.5 μM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.24%
- CAS No.: 915759-45-4
- Formule: C18H19F3N2O4S2
- Masse moléculaire:448.48
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-14648
DexamethasoneGR Agonist -
HY-10108
LY294002PI3K Inhibitor -
HY-B0579
Cyclosporin ACalcineurin Inhibitor -
HY-19987
BML-284Wnt Signaling Activator -
HY-120697
MSABWnt/β-Catenin Inhibitor -
HY-11035
WAY-262611β-Catenin Agonist -
HY-10858R
WAY 316606 (Standard)Reference Standard -
HY-10858A
WAY 316606 hydrochloridesFRP-1 Inhibitor -
HY-15721
FH535Wnt/β-catenin/PPAR Inhibitor
Publications Citing Use of MedChemExpress (MCE) WAY 316606
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
Activité biologique
Description
IC50 & Target
IC50: 0.5 μM (sFRP-1)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| U2OS | EC50 |
0.65 μM
Compound: 1, WAY-316606
|
Antagonist activity at human WNT3 expressed in human U2OS cells assessed as Wnt signaling after 16 to 18 hrs by luciferase reporter gene assay
Antagonist activity at human WNT3 expressed in human U2OS cells assessed as Wnt signaling after 16 to 18 hrs by luciferase reporter gene assay
|
[PMID: 19072540] |
In Vitro
The EC50 of WAY-316606 for Wnt-Luciferase Activity from U2-OS Cells is 0.65 μM[1]. WAY-316606 binds to secreted frizzled-related protein (sFRP)-1 inhibitor with a KD of 0.08 μM and inhibits sFRP-1 with an EC50 of 0.65 μM. WAY-316606 also binds to sFRP-2, albeit over 10 times weaker with a KD of 1 μM. Using a fluorescence polarization binding assay that employs a fluorescent probe compound and purified human sFRP-1 protein in a competitive-binding format, the IC50 for WAY-316606 is 0.5 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 915759-45-4
-
Appearance Solid
-
Masse moléculaire 448.48
-
Formule C18H19F3N2O4S2
-
Color White to off-white
-
SMILES
O=S(C1=CC(S(=O)(C2=CC=CC=C2)=O)=CC=C1C(F)(F)F)(NC3CCNCC3)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Med
Schwann cell-secreted frizzled-related protein 1 dictates neuroinflammation and peripheral nerve degeneration after neurotrauma. [Abstract]2024 Nov 19;5(11):101791. PMID: 39426375
WAY 316606 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Nov 19;5(11):101791. [Abstract]
WAY-316606 (500 nM; 5 μL; intraneural administration; every 3 days for 2 weeks) showed more myelinated axons and increased myelin sheath thickness of injured nerves isolated from mice.
WAY 316606 purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Nov 19;5(11):101791. [Abstract]
WAY-316606 (500 nM; 5 μL; intraneural administration; every 3 days for 2 weeks) promoted the axon regrowth of transected nerves in mice.
-
Commun Biol
Targeting the cochlin/SFRP1/CaMKII axis in the ocular posterior pole prevents the progression of nonpathologic myopia. [Abstract]2023 Aug 29;6(1):884. PMID: 37644183
WAY 316606 purchased from MedChemExpress. Usage Cited in: Commun Biol. 2023 Aug 29;6(1):884. [Abstract]
WAY 316606 (WAY; 2 μM; 24 h) showed no effect on the proliferation of choroidal vascular endothelial cells combined with 30 ng/mL SFRP1.
WAY 316606 purchased from MedChemExpress. Usage Cited in: Commun Biol. 2023 Aug 29;6(1):884. [Abstract]
WAY 316606 (WAY; 2 μM; 24 h) restored SFRP-1, which decreased the number of cell aggregates in the normal group.
WAY 316606 purchased from MedChemExpress. Usage Cited in: Commun Biol. 2023 Aug 29;6(1):884. [Abstract]
WAY 316606 (WAY; 2 μM; 24 h) restored SFRP-1, which induced an 18.08% increase in intracellular Ca2+ concentration in RF-6A cells.
-
Front Pharmacol
Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway. [Abstract]2021 Sep 2;12:724147. PMID: 34539406
WAY 316606 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2021 Sep 2;12:724147. [Abstract]
WAY 316606 (2 μM; 48 h) the expression of β-catenin was higher than that in lcz696-treated cells and lower than that in AngII-treated cells, suggesting that the influence of lcz696 on β-catenin is related to the expression of sFRP-1 on primary myocardial fibroblasts.
WAY 316606 purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2021 Sep 2;12:724147. [Abstract]
WAY 316606 (2 μM; 48 h) increased the mRNA expression of α-SMA and TGF-β in primary myocardial fibroblasts stimulated with angiotensin II (Ang II) and cultured with lcz696.
-
Int J Dev Neurosci
Sonic hedgehog regulates the pathfinding of descending serotonergic axons in hindbrain in collaboration with Wnt5a and secreted frizzled-related protein 1. [Abstract]2018 May:66:24-32. PMID: 29196093
WAY 316606 purchased from MedChemExpress. Usage Cited in: Int J Dev Neurosci. 2018 May:66:24-32. [Abstract]
Whole-mount anti-5-HT (black) immunostaining of embryos treated with DMSO, WAY-316606, Sfrp1 protein, Sfrp1 plus WAY-316606, or Shh in utero electroporation together with WAY-316606 injection. Black arrows indicate misdirected axons.
WAY 316606 purchased from MedChemExpress. Usage Cited in: Int J Dev Neurosci. 2018 May:66:24-32. [Abstract]
Quantification of the percentage of normal and misdirected 5-HT axons for the different groups.
Solvant et solubilité
In Vitro:
DMSO : ≥ 100 mg/mL (222.98 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Moore, WJ, et al. Modulation of Wnt Signaling Through Inhibition of Secreted Frizzled-Related Protein I (sFRP-1) with N-Substituted Piperidinyl Diphenylsulfonyl Sulfonamides. Journal of Medicinal Chemistry (2009), 52(1), 105-116. [Content Brief]
[2]. Bodine PV, et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone. 2009 Jun;44(6):1063-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2298 mL | 11.1488 mL | 22.2975 mL | 55.7438 mL |
| 5 mM | 0.4460 mL | 2.2298 mL | 4.4595 mL | 11.1488 mL | |
| 10 mM | 0.2230 mL | 1.1149 mL | 2.2298 mL | 5.5744 mL | |
| 15 mM | 0.1487 mL | 0.7433 mL | 1.4865 mL | 3.7163 mL | |
| 20 mM | 0.1115 mL | 0.5574 mL | 1.1149 mL | 2.7872 mL | |
| 25 mM | 0.0892 mL | 0.4460 mL | 0.8919 mL | 2.2298 mL | |
| 30 mM | 0.0743 mL | 0.3716 mL | 0.7433 mL | 1.8581 mL | |
| 40 mM | 0.0557 mL | 0.2787 mL | 0.5574 mL | 1.3936 mL | |
| 50 mM | 0.0446 mL | 0.2230 mL | 0.4460 mL | 1.1149 mL | |
| 60 mM | 0.0372 mL | 0.1858 mL | 0.3716 mL | 0.9291 mL | |
| 80 mM | 0.0279 mL | 0.1394 mL | 0.2787 mL | 0.6968 mL | |
| 100 mM | 0.0223 mL | 0.1115 mL | 0.2230 mL | 0.5574 mL |
WAY 316606 Related Classifications
HY-10858 Related Classifications
Powered by Bioz